Advertisement
A conference call to review the results will begin at 2:00 p.m. PDT(5:00 p.m. EDT) and will be hosted by Euan S. Thomson, Ph.D., president andchief executive officer and Robert E. McNamara, senior vice president andchief financial officer.
Advertisement
The conference call dial-in numbers are 1-866-575-6539 (USA) or1-913-981-5530 (International), Access Code: 9058024. In addition, a dial-upreplay of the conference call will be available beginning August 19, 2008 at5:00 p.m. PDT (8:00 p.m. EDT) and ending on August 29, 2008. The replaytelephone number is 1-888-203-1112 (USA) or 1-719-457-0820 (International),Access Code: 9058024.
A live webcast of the call will also be available from the InvestorRelations section of the corporate Web site at http://www.accuray.com. Awebcast replay can be accessed on the corporate Web site beginning on August19, 2008 at approximately 5:00 p.m. PDT (8:00 p.m. EDT). The replay willremain available until Accuray announces its results for the first quarter offiscal 2009, ending September 27, 2008.
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only roboticradiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlledrobotic mobility, the CyberKnife System automatically tracks, detects andcorrects for tumor and patient movement in real-time throughout the treatment.This enables the CyberKnife System to deliver high-dose radiation withpinpoint precision, which minimizes damage to surrounding healthy tissue andeliminates the need for invasive head or body stabilization frames.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is aglobal leader in the field of radiosurgery dedicated to providing an improvedquality of life and a non-surgical treatment option for those diagnosed withcancer. Accuray develops and markets the CyberKnife Robotic RadiosurgerySystem, which extends the benefits of radiosurgery to include extracranialtumors, including those in the spine, lung, prostate, liver and pancreas. Todate, the CyberKnife System has been used to treat more than 40,000 patientsworldwide and currently more than 130 systems have been installed in leadinghospitals in the Americas, Europe and Asia. For more information, please visithttp://www.accuray.com.
SOURCE Accuray Incorporated
